Boosting targeted tumor therapies

Sapreme Technologies B.V. is a Dutch Biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics using proprietary endosomal escape enhancers.


Sapreme was founded in 2016 by Aglaia Oncology Fund II. The Company develops new technologies within the field of macromolecule therapeutics such as antibody-drug conjugates and oligonucleotide-based therapeutics, based on intellectual property originating from the Charité – Universitätsmedizin Berlin (Charité) and Freie Universität Berlin (FUB). Sapreme develops a proprietary technology to ensure efficient escape of macromolecule therapeutics from endosomes (ENDOSCAPE®), currently the major hurdle in efficient drug target engagement. Sapreme R&D facilities are located at the Life Science Incubator in Utrecht at the Utrecht Science Park. The company has R&D partnerships with Charité, FUB and University of Ghent (VIB).

Ruben Postel, CSO

Ruben is the scientific founder of Sapreme and was previously CSO of the biotech company SomantiX. He worked as a postdoc at the Netherlands Cancer Institute (NKI-AvL) and holds a PhD in molecular biology and genetics from the Hubrecht Institute.

Ernst Geutjes, acting Managing Director

Ernst is associate at Aglaia and was in his previous role as business developer involved in the formation of a number of biotech start-ups. He holds a PhD in molecular cancer genetics from the Netherlands Cancer Institute (NKI-AvL).


1. Endolysosomal trapping of macromolecules

Macromolecule therapeutics targeting intracellular targets are usually dependent on receptor-mediated endocytosis and consequent release from the endo-lysosomal compartment. The therapeutic efficacy of such drugs is therefore strongly dependent on sufficient release of these drugs from endo-lysosomal vesicles before degradation. The endo-lysosomal membranes, however, are evolutionary conserved barriers that prohibit efficient cytoplasmic access of such foreign substances. Therefore cytosolic delivery of macromolecule therapeutics requires very challenging technical optimizations, or specialized drug delivery platforms, if feasible at all. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem.

2. ENDOSCAPE® technology

Researchers at the Charité and FUB have discovered a class of non-immunogenic saponins, glycosylated triterpenoids, that can selectively permeabilize endo-lysosomal membranes to enhance endosomal escape of trapped cargo without affecting plasma membrane integrity in a pH-dependent manner. Up to 1.000.000 fold increase in cancer cell killing activity, whereas up to 100-fold increased efficacy in tumor reduction have been observed in various mouse tumor models when these proprietary saponins were combined with antibody-conjugated toxins. In collaboration with the Charité, FUB and others, Sapreme is developing a proprietary module (ENDOSCAPE®) that can be incorporated in the design of current and future targeted cancer therapeutics as well as other non-oncology therapeutics that could benefit from enhanced cytoplasmic delivery (e.g. gene therapy).

3. Biotechnological production of SPT-001 and SPT-003

Sapreme’s saponins SPT-001 and SPT-003 are purified from plant material using proprietary isolation methods. Sapreme is collaborating with the research group of Prof. Alain Goossens at the University of Ghent (VIB) to further optimize large scale production of SPT-001 and SPT-003.

Follow this link for more background information.



Sapreme is collaborating with the research group of Prof. Hendrik Fuchs at the Charité – Universitätsmedizin in Berlin. His group has strong expertise in targeted delivery of macromolecular drugs into the cytosol of cells by use of endosomal escape enhancers. Sapreme is working with Charité to develop the ENDOSCAPE® technology for delivery of targeted toxins.


Sapreme is collaborating with the research group of Dr. Alexander Weng at the department of Prof. Matthias Melzig at the Freie Universität in Berlin (FUB). The group of Dr. Weng has considerable expertise in identifying and characterization of novel endosomal escape enhancers from natural sources and the development of non-viral gene carriers. Sapreme is working with the FUB to develop the ENDOSCAPE® technology for targeted delivery of DNA/RNA.


Sapreme is collaborating with the research group of Prof. Alain Goossens at the University of Ghent (VIB). His group has a long-standing trackrecord in developing plant cultures that produce high levels of secondary metabolites such as saponins via metabolic engineering. Sapreme is working with the VIB to develop plant/root culture lines that produce high amounts of Sapreme’s proprietary saponins.


Aglaia is an investment firm with a 100% focus on oncology. Aglaia provides extensive know-how in cancer drug development and closely collaborates with inventors and entrepreneurs to develop early-stage technology into clinically and commercially successful biotech companies.


Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

UTRECHT, the Netherlands, February 20, 2019 / B3C newswire / — Sapreme Technologies, a privately-held biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M€ grant together with a multidisciplinary consortium including 11 other academic and industrial parties. The grant was provided by the European Union (EU) through Horizon 2020 to develop a non-viral based gene therapy using Sapreme’s proprietary endosomal escape enhancers.

Ruben Postel, CSO of Sapreme Technologies, “We are pleased to see that the EU has recognized the great potential of the ENDOSCAPE project and the expert multi-disciplinary consortium developing a novel oligonucleotide delivery technology for treatment of cancer and haemophilia patients”

Ernst Geutjes, acting Managing Director, “The fact that the EU awarded the proposal with the maximum score demonstrates the potential of Sapreme’s proprietary endosomal escape enhancement technology as well as the exceptional quality of the proposal and the consortium spearheaded by Sapreme and Charité – Universitätsmedizin Berlin”


Link to the press release




Sapreme is seeking a Senior Technician Antibody conjugates analysis

 Job description

Sapreme Technologies is a privately-owned biotech company which develops a disruptive proprietary technology platform (ENDOSCAPE®) enabling the development of novel treatments including antibody-drug conjugates and oligonucleotide-based drugs. You will join an exciting and innovative working environment and be part of a mission to develop new medicines for cancer and other diseases. You will become part of a small ambitious team which develops a variety of drug prototypes, originating from the ENDOSCAPE  platform, both in-house and in collaboration with a number of academic and industrial partners. You will be responsible for biological characterization of a multitude of bio-conjugates including antibody-drug conjugates and other proprietary medicinal scaffolds according to industry-standard quality systems. You will contribute to internal project meetings and will be under the supervision of the Senior Scientist of Sapreme Technologies.

Tasks and Responsibilities

  • You will execute the R&D plans as planned together with the Senior Scientist
  • You are practically profoundly skilled in biological screening and assay development
  • You are comfortable running multiple projects in parallel
  • You enjoy pro-actively proposing solutions and troubleshooting
  • You are accustomed to work-up and analysis of biological material (tissue, blood) sourced from animals
  • You have some basic knowledge of protein / peptide chemistry (cross-linking / conjugation and labeling)
  • You are accustomed to setting-up quality systems, procedures and work documentation
  • You document results accurately and are focused on output and results
  • You contribute to internal meetings and project meetings with collaborators
  • You are accustomed to adhering to deadlines and accept an occasionally enhanced workload
  • You enjoy working in a multi-disciplinary team
  • You are driven by translation of science into products
  • You preferably contribute to the scientific discussions


Key requirements

  • You have a completed HLO education or equivalent
  • You have at least 3 years of working experience in the biotech/pharma/CRO or other relevant industry
  • You have experience with functional assays such as MTS/MTT, proliferation, apoptosis
  • You have experience in analytics including DNA, RNA, FACS, Western Blot, qRT-PCR, cloning, IHC, IF
  • You are familiar with basic statistical and data analysis software such as Excel, GraphPad Prism, FlowJo etc
  • Excellent proficiency in English
  • You have experience in working with proteins including antibodies
  • You have preferably worked in the oncology field
  • You have preferably worked with bio-conjugates
  • Knowledge of, and/or work experience with, regulatory guidelines for product related assays is preferred

The job is based on a contract for 40 hour/week and salary will be based on relevant work experience.

Should you meet these requirements and be interested in applying for this job, please send your motivation and resume letter to Ruben Postel at Enquiries: +31 30 760 09 76. We look forward receiving your application.

Location: Life Sciences Incubator, Yalelaan 62 Utrecht



+31 30 760 09 76


LSI, Room 2.09
3584 CM Utrecht
The Netherlands